Edwards Lifesciences Discloses Insider Sale Ahead of Q3 Earnings
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
Edwards Lifesciences filed insider trading documents with the SEC. The filing disclosed that Vice President Daniel Lippis sold 619 shares of the firm’s stock on October 8th, at an average price of $85.65 per share. The company is scheduled to post its Q3 2026 results after the market closes on November 4th.
From tickerreport.com
Why it matters
The disclosure of the executive sale is part of the regulatory requirements set by the SEC. This activity comes as Edwards Lifesciences prepares to announce Q3 2026 earnings, which analysts expect to include revenue of $1.68 billion.
From tickerreport.com
Who's involved
- Edwards LifesciencesAmerican medical technology company subject to the insider trading disclosure
- SECRegulatory body that received the insider trading filing
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Edwards LifesciencesSpeculative
Edwards Lifesciences might experience shifts in investor demand or stock prices following the disclosure of the executive stock sale.
Keep exploring
The entities involved
-
Edwards Lifesciences
American medical technology company
Nothing else this week.
-
SEC
Slovak company
Related events
- State Street disclosed insider trades to the SEC on October 14, 2026.
- Insider purchase disclosed via SEC filing for Transcontinental Realty Investors, Inc. on August 6, 2026.
- Stewart Information Services Corporation filed required disclosures regarding insider transactions with the SEC on August 27, 2026.
- SoFi disclosed insider trades via an SEC filing on October 19, 2026.
- Insider transactions disclosed in legal filings with the SEC involving Applied Materials.